The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well reported. The addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-activated protein kinase pathway. The combination of dabrafenib with the MEK inhibitor trametinib dimethyl sulfoxide (CombiDT therapy) increases response rate and survival compared with a BRAF inhibitor alone. Clinical trials have suggested that CombiDT therapy induces fewer cutaneous toxic effects than a single-agent BRAF inhibitor. To our knowledge, a direct comparison has not been performed before.
RESULTS
The most common cutaneous adverse effects seen in patients receiving the single-agent BRAF inhibitor dabrafenib or vemurafenib included Grover disease ( CONCLUSIONS AND RELEVANCE This study confirms that the prevalence of cutaneous toxic effects differs among vemurafenib, dabrafenib, and CombiDT therapies. Cutaneous squamous cell carcinoma is the most concerning cutaneous toxic effect related to BRAF inhibitor monotherapy that did not appear with CombiDT therapy. Although CombiDT therapy has an improved profile of cutaneous toxic effects, continuous dermatologic assessments should be provided for all patients when receiving these treatments.
T he BRAF inhibitors vemurafenib and dabrafenib mesylate have revolutionized the treatment of stage IV metastatic melanoma with a survival benefit over dacarbazine chemotherapy in BRAF-mutant melanoma. 1, 2 The MEK inhibitor trametinib dimethyl sulfoxide has also shown a survival benefit in the same population. 3 The combination of dabrafenib and trametinib improves the response rate and progression-free survival compared with dabrafenib alone and overall survival compared with vemurafenib. 4 These agents are associated with a number of cutaneous toxic effects, many of which are reduced when BRAF and MEK inhibitors are given concurrently. 5 Cutaneous squamous cell carcinomas (SCCs)
constitute the toxic effect of most concern associated with BRAF inhibitor monotherapy and have been reported with the use of vemurafenib and dabrafenib, 6 whereas acneiform eruptions are more frequent with the use of the MEK inhibitor trametinib. 7 In this study, we describe the cutaneous toxic effects arising in a large cohort of patients treated with a singleagent BRAF inhibitor (dabrafenib or vemurafenib) or a combination of dabrafenib and trametinib (CombiDT) for metastatic melanoma at a single institution.
Methods
We reviewed the medical records from all patients (n = 211) with advanced melanoma referred from Crown Princess Mary Cancer Care Centre for treatment at the Department of Dermatology, Westmead Hospital, from September 1, 2009, through November 30, 2013, for inclusion into the study. Patients with unresectable stages IIIC and IV melanoma who were treated with the BRAF inhibitor vemurafenib or dabrafenib alone or CombiDT therapy were included (N = 185). All patients were recruited according to the clinical trial protocols, which were approved by the Westmead Hospital independent ethics committee and performed in accordance with good clinical practice guidelines. All patients provided written and verbal informed consent. Data for the analyses were deidentified. Patients underwent full-body skin examinations by a dermatologist (P.F.-P.); 55 of 185 patients (29.7%) had an assessment before treatment and then every 4 to 8 weeks or earlier if deemed clinically necessary. On examination, any lesion suggestive of a cutaneous malignant neoplasm was photographed and underwent biopsy for further histologic evaluation. If confirmed as potentially malignant, the lesion was completely excised.
Data analysis was performed in December 2013. We performed statistical analysis using JMP 8 software (SAS Institute Inc). Owing to multiple comparisons, the Bonferroni correction method was applied to determine statistical significance (level of significance, <.0023). 8 
Results

Patient Characteristics
We included a total of 185 patients in the study. One hundred fifty-five patients were treated with a single-agent BRAF inhibitor (119 with dabrafenib and 36 with vemurafenib), and 30 patients were treated with CombiDT therapy.
We found no statistically significant differences in sex distribution between vemurafenib (27 of 36 patients [75.0%] were men), dabrafenib (84 of 119 patients [70.6%] were men), and CombiDT therapy (16 of 30 patients [53.3%] were men). Patients treated with vemurafenib were significantly older than those treated with dabrafenib (60 vs 53 years of age; P = .045), but no significant differences were found between other treatment groups. We found no statistically significant differences in treatment duration, with the median treatment duration of 26 (range, 7-98) weeks for vemurafenib, 33 (range, 3-211) weeks for dabrafenib, and 42 (range, 7-145) weeks for CombiDT therapy.
Cutaneous Toxic Effects
The BRAF inhibitor-induced cutaneous toxic effects were near universal for patients treated with BRAF inhibitor monotherapy (142 of 155 patients [91.6%]). They were also prevalent in those treated with CombiDT therapy (23 of 30 patients [76.7%]).
BRAF Inhibitor Monotherapy
Common cutaneous toxic effects seen in patients receiving BRAF inhibitor monotherapy included verrucal keratosis, Grover disease, plantar hyperkeratosis, cutaneous SCC, and actinic keratosis ( Table 1) . Approximately three-quarters of patients treated with BRAF inhibitor monotherapy developed adverse effects resulting from paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway and subsequent keratinocyte hyperproliferation (eg, cutaneous SCC, verrucal keratosis, and plantar hyperkeratosis) ( Table 1) .
Verruciform keratotic squamoproliferative lesions or verrucal keratosis 9 The most relevant cutaneous adverse event, always reported as a grade 3 toxic effect in clinical trials, was the development of cutaneous SCCs. All lesions suggestive of SCC underwent biopsy or excision with clinical borders according to Australian guidelines. 10 All biopsy specimens were sent to the Department of Tissue Pathology and Diagnostic Oncology, Westmead Hospital for histopathologic evaluation and confirmation. Although we found that 13 vemurafenib-treated patients (36.1%) and 31 dabrafenib-treated patients (26.1%) developed a cutaneous SCC, the difference was not statistically significant. Photosensitivity (Figure, C) is a prevalent skin eruption in patients receiving vemurafenib that occurred in 14 of our (0.8%) developed facial and trunk erythema after minimal sun exposure.
Plantar hyperkeratosis occurred similarly in both singleagent BRAF inhibitor groups, accounting for 47 patients treated with dabrafenib (39.5%) and 14 patients treated with vemurafenib (38.9%). Plantar hyperkeratosis usually occurred at points of friction and was also seen infrequently on the hands. Follicular changes were a common but generally asymptomatic adverse effect noted in these patients. Localized folliculitis was present in 5 vemurafenib-treated patients (13.9%) and in 8 dabrafenib-treated patients (6.7%). Keratosis pilaris has also been reported to occur in patients treated with vemurafenib 11, 12 and occurred in 5 vemurafenib-treated patients (5.6%) and 2 dabrafenib-treated patients (1.7% Changes in melanocytic nevi such as hyperpigmentation, regression, and new primary melanomas were also noted. Three dabrafenib-treated patients (2.5%) developed new primary melanomas, and patients receiving both single-agent BRAF inhibitors had changes in nevi size and color.
Acneiform reactions occurred in 9 dabrafenib-treated patients (7.6%) and 1 vemurafenib-treated patient (2.8%). One patient receiving single-agent dabrafenib also developed a cystic acneiform eruption on the face, chest, and back.
In our study, the type of single-agent BRAF inhibitor (vemurafenib or dabrafenib) did not appear to affect the frequency of cutaneous toxic effects. Photosensitivity, which was more common with vemurafenib than dabrafenib treatment (14 patients [38.9%] vs 1 [0.8%], respectively P < .001), was the exception (Table 1) .
In patients receiving dabrafenib, age was a significant factor for the development of a number of cutaneous toxic effects ( Table 2 ). The mean age of patients who developed verrucal keratosis, Grover disease, cutaneous SCC, basal cell carcinoma, actinic keratosis, and eczema ranged from 57 to 67 years; for the patients developing folliculitis, the mean age was 42 years. No significant differences between sexes were noted.
CombiDT Therapy
The CombiDT group had a different profile of cutaneous adverse effects when compared with single-agent dabrafenib ( Table 3) . No verrucal keratosis, cutaneous SCC, or Grover disease were seen in any patients receiving CombiDT therapy (P < .001 for all). The most common adverse effect noted in patients receiving CombiDT therapy was folliculitis (12 of 30 patients [40.0%]), which was more frequent than in patients receiving single-agent dabrafenib (8 of 119 patients [6.7%]; P < .001), but the clinical presentation was similar (Figure, D) . Plantar hyperkeratosis and acneiform reactions each occurred in 5 patients receiving the CombiDT treatment (16.7% for each). Only 1 CombiDT-treated patient (3.3%) developed facial and trunk erythema after minimal sun exposure. 
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Three patients treated with CombiDT (10.0%) developed localized or whole-body maculopapular eruptions or drug reactions with the concomitant use of penicillin, methotrexate, and anticonvulsants. Seven of the patients treated with CombiDT had been treated previously with dabrafenib and 1 had been treated previously with vemurafenib. After switching to CombiDT therapy, 2 of these patients experienced a reduction in frequency and 6 experienced resolution of cutaneous SCC, verrucal keratosis, Grover disease, and plantar hyperkeratosis.
Discussion
We compared the cutaneous toxic effects of BRAF inhibitor monotherapy and CombiDT therapy in a large cohort of patients who have undergone comparable dermatologic assessments. Benign and malignant squamous proliferative disorders related to vemurafenib and dabrafenib have been recognized and reported in the literature. 9, 13, 14 Both drugs are associated with the development of cutaneous SCC and other activation of ERK and consequently leads to a reduction in squamoproliferative toxic effects to the skin. 5, 17 Verrucal keratoses are the most common cutaneous toxic effects related to single-agent BRAF inhibitor use. These hyperkeratotic premalignant lesions may be a marker of increased risk for development of BRAF inhibitor-induced cutaneous SCC. 18 Although they occurred in 105 of the 155 patients receiving single-agent therapy (67.7%), they are much less frequently reported throughout the medical literature, which may be a result of their misclassification as a nonspecific rash or hyperkeratosis. 1, 19, 20 Patients were treated according to their clinical presentations, with cryotherapy and shave biopsies being the most common therapies. From our data, verrucal keratosis development occurred independently of the patient's sex but increased with increasing age. Although rates of cutaneous SCC have been reported to be higher in patients receiving vemurafenib vs dabrafenib, 21 and although we found that 36.1% of vemurafenib-treated and 26.1% of dabrafenib-treated patients developed a cutaneous SCC, the difference was not statistically significant. This result could be owing to the small sample size and the statistically significant difference in age between vemurafenibtreated (mean age, 60 years) and dabrafenib-treated (mean age, 53 years) patients (P = .045).
Another underreported skin eruption is Grover disease, which has been associated previously with the use of dabrafenib 9 and vemurafenib, 22 but may have also been misclassified as a nonspecific rash. The etiology of Grover disease is unknown but, given the significant difference be- 25 Despite patients being advised about sun-protective measures at every visit, most of the affected patients developed a spectrum from mild sun-related erythema to severe sunburn with or without associated blistering in the presence of minimal or indirect sun exposure. Treatment varied according to the extensiveness and severity of the phototoxic effects. The use of topical moisturizers and mild topical corticosteroids was sufficient in most cases. One case needed oral corticosteroids and protective dressings for severe sunburn.
The reported incidence of trametinib-induced acneiform reactions is 80%, 3, 7 with much lower rates noted when trametinib is combined with dabrafenib. 5 Uribe et al 26 have
reported an acneiform reaction emerging after cessation of CombiDT treatment, which was proposed to be a result of trametinib's longer half-life. In our patients, acneiform reactions were localized to the face and trunk, both areas with a high presence of sebaceous glands. Topical treatments (clindamycin hydrochloride) and oral doxycycline hydrochloride were sufficient in most of our cases, with only 1 patient receiving single-agent dabrafenib requiring oral retinoid (isotretinoin). For this specific case, the symptoms were controlled, but the condition did not resolve completely.
No cases of palmar-plantar erythrodysesthesia occurred despite it being reported in approximately 10% of patients treated with vemurafenib. 27 Conversely, plantar hyperkera- Therefore, paradoxical activation of the MAPK pathway may also play a role. Hyperpigmentation, regression, and new nevi were also noted in a large number of our patients. Testing for a BRAF mutation was not performed in our patients who developed new primary melanomas during BRAF inhibitor therapy.
Conclusions
Patients treated with BRAF inhibitors alone or in combination with the MEK inhibitor trametinib require careful and ongoing dermatologic monitoring throughout their treatment.
CombiDT therapy has an improved profile of cutaneous toxic effects compared with BRAF inhibitor monotherapy. In the spectrum of squamoproliferative disorders, cutaneous SCC remains the most concerning cutaneous toxic effect related to BRAF inhibitor monotherapy and requires accurate clinicopathologic diagnosis and appropriate management in a timely manner. Recognition of the variety of cutaneous toxic effects associated with these different therapies, including the predisposing risk factors for their development, is important with the purpose of ensuring appropriate rapid intervention and thereby abrogating the need to delay or even withhold these essential treatments.
